Main Article Content

At present two prophylactic human papilloma virus (HPV) vaccines are commercially available. The Tetravalent vaccine against infection with four VPH types (6, 11, 16, and 18) distributed in the national program in Colombia and the Bivalent vaccine against the VPH types 16 and 18, respectively.  The efficacy and safety of both vaccines has periodically been assessed and they have been declared efficacious and safe by the health authorities of several countries and the Global Advisory Committee on Vaccine Safety ( GACVS ) of the World’s Health Organization (WHO).In its report of March 2014 the GACVS analyzed the evidence of the relationship between the  Human Papillomavirus Vaccine with  >175 million of doses distributed worldwide and autoimmune diseases, particularly Multiple Sclerosis, Aluminum as adjuvant, Vasculitis caused by vaccine DNA fragments and the Complex Regional Pain Syndrome described in Japan.   The Committee ratified the strict vaccine safety control and based on a thorough examination of existing evidence, reaffirmed that the risk-benefit profile remains favorable. The case of the children of Carmen de Bolivar in Colombia has been described by several authors in other countries as "Massive Psychogenic Event", which has absolute no relationship with the vaccine but its high media dissemination resulted into disastrous consequences for the national vaccination program

Julio Cesar Reina, Centro Médica Imbanaco

Profesor Titular y Emérito (J), Departamento de Pediatría, Universidad del Valle. Pediatra Investigador Centro Medico Imbanaco, Cali, Colombia

Nubia Muñoz, Ex-jefe de Epidemiologia en la Agencia Internacional para la Investigación del Cáncer en Lyon, Francia y Profesora Emérita del Instituto de Cancerología de Colombia.

Ex-jefe de Epidemiologia en la Agencia Internacional para la Investigación del Cáncer en Lyon, Francia y Profesora Emérita del Instituto de Cancerología de Colombia.
Reina, J. C., & Muñoz, N. (2014). Vaccine against human Papilloma Virus. Colombia Medica, 45(3), 94–95.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(5):325–339.

Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human Papillomavirus recombinant vaccine. JAMA. 2009;302:750–757.

Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29:8279–8284.

Arnheim-Dahlström L, Pasternak B, Svaström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906–f5906.

Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275(4):398–408.

OMS [30 August 2014];Global Advisory Committee on Vacine Safety. 20140312 a Available from: safety/committee/topics/hpv.

Mitkus RJ, King DB, Hess MA, Forshee RA, Walderhaug MO. Updated Aluminum pharmacokinetics following infant exposures through diet and vaccines. Vaccine. 2011;29:9538–9543.

Buttery JP, Madin S, Crawford NW, Elia S, La Vincente S, Hanieh S, et al. Mass psychogenic response to human papillomavirus vaccination. Med J Aust. 2008;189(5):261–262.


Download data is not yet available.
Received 2014-09-24
Accepted 2014-09-29
Published 2014-09-30